Naproxen Sodium is an NSAID (propionic acid derivative) indicated for pain, arthritis, dysmenorrhea and fever. We supply it to US manufacturers of tablets and capsules.
Data from PubChem (CID 23681059) and FDA’s substance registry
CAS number
26159-34-2
Molecular formula
C14H13NaO3
Molecular weight
252.2g/mol
FDA UNII
IUPAC name
sodium (2S)-2-(6-methoxynaphthalen-2-yl)propanoate
InChIKey
CDBRNDSHEYLDJV-FVGYRXGTSA-M
- Appearance
- White to creamy crystalline powder.
- Solubility
- Soluble in water and methanol, sparingly soluble in alcohol, and practically insoluble in chloroform and toluene.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Strengths are labeled two ways. OTC 220 mg tablets are stated as the sodium salt, and prescription tablets as naproxen: 275 mg of the salt delivers 250 mg.
On the US market
- Reference product
- AnaproxNDA 018164
- Approved ANDAs
- 18 with a marketed product
- Approved forms and strengths
- Tablet 220 mg, 250 mg, 500 mg
- Extended-release tablet 375 mg, 500 mg, 750 mg
- Capsule 200 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com